Protalix BioTherapeutics Inc. and Chiesi Farmaceutici SPA plan to file for accelerated approval of Fabry disease drug pegunigalsidase alfa in the first quarter of next year after talks with US Food and Drug Administration found a surrogate path forward.
The partners are testing the drug, also known as PRX-102, in three Phase III trials to establish it as a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?